Clinical Trial Update: Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study evaluating Pazopanib in combination with Cyclophosphamide for platinum-resistant recurrent epithelial ovarian cancer has completed enrollment/s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Pazopanib (Pazopanib)

Snippet

Sponsor: Priv.-Doz. Dr. med. Joachim Rom | Conditions: Epithelial Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED